BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29090974)

  • 1. Rising Costs of Drug/Insulin Treatment for Diabetes: A Perspective from India.
    Misra A; Mukherjee R; Luthra A; Singh P
    Diabetes Technol Ther; 2017 Dec; 19(12):693-698. PubMed ID: 29090974
    [No Abstract]   [Full Text] [Related]  

  • 2. Diabetes costs rise, but so does adherence.
    Manag Care; 2005 Apr; 14(4):54. PubMed ID: 15898213
    [No Abstract]   [Full Text] [Related]  

  • 3. [Insulin analogues--which dimension should be discussed?].
    Verspohl EJ
    Med Monatsschr Pharm; 2006 Jun; 29(6):198-9. PubMed ID: 16792195
    [No Abstract]   [Full Text] [Related]  

  • 4. The market in diabetes.
    Hauber A; Gale EA
    Diabetologia; 2006 Feb; 49(2):247-52. PubMed ID: 16416145
    [No Abstract]   [Full Text] [Related]  

  • 5. Comment and reply on: Relative efficacy/effectiveness and relative costs of treatment with insulin glargine and insulin detemir.
    Freemantle N; Stella P; Munro V
    Curr Med Res Opin; 2007 Aug; 23(8):1761-2; author reply 1762-4. PubMed ID: 17588305
    [No Abstract]   [Full Text] [Related]  

  • 6. [Epidemiology and costs of diabetes mellitus in Germany].
    Hauner H
    Dtsch Med Wochenschr; 2005 Jul; 130 Suppl 2():S64-5. PubMed ID: 15988670
    [No Abstract]   [Full Text] [Related]  

  • 7. Insulin therapy in NWFP Pakistan.
    Ahmad M
    J Ayub Med Coll Abbottabad; 2001; 13(3):36-7. PubMed ID: 11873397
    [No Abstract]   [Full Text] [Related]  

  • 8. [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study].
    von Ferber L; Köster I; Hauner H
    Med Klin (Munich); 2006 May; 101(5):384-93. PubMed ID: 16685485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More from PHARMAC on long-acting insulin analogues: insulin glargine now funded.
    Moodie P
    N Z Med J; 2006 Jun; 119(1236):U2040. PubMed ID: 16807582
    [No Abstract]   [Full Text] [Related]  

  • 10. Evolution of insulin patents and market exclusivities in the USA.
    Luo J; Kesselheim AS
    Lancet Diabetes Endocrinol; 2015 Nov; 3(11):835-7. PubMed ID: 26453281
    [No Abstract]   [Full Text] [Related]  

  • 11. [Diabetes care in sub-Saharan Africa].
    Labie D
    Med Sci (Paris); 2007 Mar; 23(3):320-2. PubMed ID: 17349296
    [No Abstract]   [Full Text] [Related]  

  • 12. Expenditures and Prices of Antihyperglycemic Medications in the United States: 2002-2013.
    Hua X; Carvalho N; Tew M; Huang ES; Herman WH; Clarke P
    JAMA; 2016 Apr; 315(13):1400-2. PubMed ID: 27046369
    [No Abstract]   [Full Text] [Related]  

  • 13. Small daily doses of insulin: wasting money?
    Carter A
    J Diabetes Sci Technol; 2012 Jan; 6(1):225. PubMed ID: 22401345
    [No Abstract]   [Full Text] [Related]  

  • 14. The Insulin Boom. WHY THE COST OF THIS LIFESAVING DRUG IS REACHING NEW HEIGHTS.
    Tsai A
    Diabetes Forecast; 2016; 69(2):32-7. PubMed ID: 27048046
    [No Abstract]   [Full Text] [Related]  

  • 15. [Insulin. A comparison of commercial preparations].
    Menz W
    Med Monatsschr Pharm; 2006 Mar; 29(3):97-100. PubMed ID: 16550883
    [No Abstract]   [Full Text] [Related]  

  • 16. The impact of biosimilar insulins on the diabetes landscape.
    White J; Wagner A; Patel H
    J Manag Care Spec Pharm; 2022 Jan; 28(1):91-98. PubMed ID: 34726499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in the prescription and cost of diabetic medications and monitoring equipment in England 1991-2004.
    Patel H; Srishanmuganathan J; Car J; Majeed A
    J Public Health (Oxf); 2007 Mar; 29(1):48-52. PubMed ID: 17124257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature.
    Salas M; Hughes D; Zuluaga A; Vardeva K; Lebmeier M
    Value Health; 2009 Sep; 12(6):915-22. PubMed ID: 19402848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs Associated With Using Different Insulin Preparations.
    Tylee T; Hirsch IB
    JAMA; 2015 Aug; 314(7):665-6. PubMed ID: 26284715
    [No Abstract]   [Full Text] [Related]  

  • 20. Budget impact analysis of insulin therapies and associated delivery systems.
    Lee LJ; Smolen LJ; Klein TM; Foster SA; Whiteman D; Jorgenson JA; Hultgren S
    Am J Health Syst Pharm; 2012 Jun; 69(11):958-65. PubMed ID: 22610028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.